BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD New post-hoc analysis...
Mont Saint Guibert Waals Gewest France General Seitosei Actifin Ghislaine Gasparetto Neil Hunter Michelle Boxall
Source: marketscreener.com